Cargando…
Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions
Acute heart failure (AHF) is characterized by high morbidity and mortality and high costs. Although the treatment of AHF has not changed substantially in recent decades, it is becoming clear that treatment strategies for AHF need to address both the immediate hemodynamic abnormalities giving rise to...
Autor principal: | Díez, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115190/ https://www.ncbi.nlm.nih.gov/pubmed/24590581 http://dx.doi.org/10.1007/s40256-014-0069-0 |
Ejemplares similares
-
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection
por: Díez, Javier, et al.
Publicado: (2016) -
Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023) -
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017) -
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013) -
Hemodynamic Monitoring in the Acute Management of Pediatric Heart
Failure
por: Tsang, Rocky, et al.
Publicado: (2016)